← Back to Search

PET/MR for Kidney Cancer

N/A

Waitlist Available

Led By David Lalush

Research Sponsored by UNC Lineberger Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up pet/mr scans will be taken within four weeks prior to surgery. tissue samples will be taken at the time of surgery. (from the pet/mr scan to surgery day=day 1)

Awards & highlights

Study Summary

This trial is looking at whether combining PET and MRI scans can help doctors better understand the different types of clear cell renal cell carcinoma (ccRCC) and make better decisions about treatment.

Eligible Conditions

Kidney Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ pet/mr scans will be taken within four weeks prior to surgery. tissue samples will be taken at the time of surgery. (from the pet/mr scan to surgery day=day 1)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~pet/mr scans will be taken within four weeks prior to surgery. tissue samples will be taken at the time of surgery. (from the pet/mr scan to surgery day=day 1)

This trial's timeline: 3 weeks for screening, Varies for treatment, and pet/mr scans will be taken within four weeks prior to surgery. tissue samples will be taken at the time of surgery. (from the pet/mr scan to surgery day=day 1) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Correlation Between PET Activity Distribution and Tumor Subtype Composition

Trial Design

1Treatment groups

Experimental Treatment

Group I: PET/MRExperimental Treatment1 Intervention

Each patient will undergo one combined PET/MR scan prior to surgery. The PET/MR scans are for research purposes and not part of the patient's standard of care.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

PET/MR

2018

Completed Phase 3

~100

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

UNC Lineberger Comprehensive Cancer CenterLead Sponsor

351 Previous Clinical Trials

88,327 Total Patients Enrolled

David LalushPrincipal InvestigatorUNC Biomedical Engineering

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How can I join this research project?

"This study is looking for 17 patients that have been diagnosed with carcinoma. The ideal candidate is aged 18 to 99 and meets the following additional requirements: They must be able to provide informed consent, have a tumor size of 7 cm or greater, be available for a PET scan within 4 weeks of surgery, not have any prior malignancies, and be negative for pregnancy."

Answered by AI

Are we still welcoming volunteers for this experiment?

"The study is still recruiting patients, according to the information available on clinicaltrials.gov. The listing for this clinical trial was first posted on October 1st, 2020, and was edited most recently on October 27th, 2022."

Answered by AI

Would this medication be appropriate for middle-aged individuals?

"The criteria to be eligible for this particular study is that the patient is aged between 18-99. There are 83 clinical trials currently underway for patients younger than 18 and 2635 for those older than 65."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

PET/MR Characterization of Renal Cell Carcinomas

2020. "PET/MR Characterization of Renal Cell Carcinomas". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04271254.